Table 3 Prior treatments and clinical outcomes to axitinib and first subsequent therapy
From: Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
Patient ID | Therapies prior to Axitinib | Duration of axitinib treatment (mon) | Best response to Axitinib | Reason for discontinuation | Interval from End of Axitinib Therapy to Start of Subsequent Therapy (weeks) | Subsequent therapy 1 | Best response |
|---|---|---|---|---|---|---|---|
1 | IL-2 plus IFN | 18 | PR | PD | 28 | Sunitinib | PR |
2 | IL-2 plus IFN | 90 | PR | PD | 1 | Bevacizumab | SD |
3 | IL-2 plus IFN | 24 | SD | PD | 41 | Sunitinib | Not evaluable |
4 | IL-2 | 6 | PR | PD | 0 | Pazopanib | PD |
5 | IL-2 plus thalidomide, Sorafenib | 41 | PR | PD | 2 | Sunitinib | SD |
6 | IL-2/Bevacizumab | 18 | SD | PD | 3 | Pazopanib | SD |
7 | IL-2, sunitinib, IFN, sorafenib | 8 | SD | PD | 1 | Bevacizumab | PD |
8 | IL-2 plus IFN, BAY 43-9006, Sorafenib | 31 | PR | Toxicity, RPLSa | 10 | Temserolimus | SD |
9 | IFN,vinblastin plus thalidomide,IL-2, Gemcitabine plus Capecitabine, Sorafenib | 53 | PR | Toxicity, MIb | 7 | Pazopanib | SD |
10 | IFN, Sunitinib, Sorafinib | 8 | SD | PD | 35 | Temserolimus | SD |
11 | IFN, IL-2/thalidomide, IL-2/IFN, sunitinib, sorafenib | 11 | SD | PD | 2 | Bevacizumab | PD |
12 | ABX-EGF, CC-5013, 5FU/suramin, Sorafinib | 4 | SD | PD | 5 | Sunitinib | SD |
13 | Sunitinib | 1 | PD | PD | 0 | Everolimus | Not evaluable |
14 | Sunitinb | 3 | SD | PD | 1 | Everolimus | PD |
15 | Sunitinib | 3 | SD | PD | 0 | Everolimus | SD |
16 | Sorafenib | 19 | PR | PD | 2 | Sunitinib | PD |
17 | Sorafenibb | 41 | PR | PD | 2 | Sunitinib | SD |
18 | Temsirolimus | 6 | PR | Toxicity | 0 | Pazopanib | SD |
19 | None | 29 | PR | PD | 3 | Everolimus | SD |
20 | None | 20 | PR | PD | 2 | Everolimus | PD |
21 | None | 2 | CR | Toxicity | 0 | Pazopanib | PR |
22 | None | 4 | SD | PD | 32 | Sunitinib | SD |
23 | None | 13 | PR | PD | 2 | Bevacizumab | PD |
24 | None | 6 | SD | PD | 2 | Pazopanib | SD |
25 | None | 6 | PR | PD | 3 | Sunitinib | Not evaluable |